Varela-Rohena Angel, Molloy Peter E, Dunn Steven M, Li Yi, Suhoski Megan M, Carroll Richard G, Milicic Anita, Mahon Tara, Sutton Deborah H, Laugel Bruno, Moysey Ruth, Cameron Brian J, Vuidepot Annelise, Purbhoo Marco A, Cole David K, Phillips Rodney E, June Carl H, Jakobsen Bent K, Sewell Andrew K, Riley James L
Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6160, USA.
Nat Med. 2008 Dec;14(12):1390-5. doi: 10.1038/nm.1779. Epub 2008 Nov 9.
HIV's considerable capacity to vary its HLA-I-restricted peptide antigens allows it to escape from host cytotoxic T lymphocytes (CTLs). Nevertheless, therapeutics able to target HLA-I-associated antigens, with specificity for the spectrum of preferred CTL escape mutants, could prove effective. Here we use phage display to isolate and enhance a T-cell antigen receptor (TCR) originating from a CTL line derived from an infected person and specific for the immunodominant HLA-A(*)02-restricted, HIVgag-specific peptide SLYNTVATL (SL9). High-affinity (K(D) < 400 pM) TCRs were produced that bound with a half-life in excess of 2.5 h, retained specificity, targeted HIV-infected cells and recognized all common escape variants of this epitope. CD8 T cells transduced with this supraphysiologic TCR produced a greater range of soluble factors and more interleukin-2 than those transduced with natural SL9-specific TCR, and they effectively controlled wild-type and mutant strains of HIV at effector-to-target ratios that could be achieved by T-cell therapy.
HIV改变其HLA-I限制性肽抗原的能力很强,这使其能够逃避宿主细胞毒性T淋巴细胞(CTL)的攻击。然而,能够靶向HLA-I相关抗原、对首选CTL逃逸突变体谱具有特异性的疗法可能会被证明是有效的。在这里,我们利用噬菌体展示技术分离并增强了一种T细胞抗原受体(TCR),该受体源自一名感染者的CTL系,对免疫显性的HLA-A(*)02限制性、HIV gag特异性肽SLYNTVATL(SL9)具有特异性。我们制备出了高亲和力(K(D) < 400 pM)的TCR,其结合半衰期超过2.5小时,保留了特异性,靶向HIV感染细胞,并识别该表位的所有常见逃逸变体。用这种超生理TCR转导的CD8 T细胞比用天然SL9特异性TCR转导的细胞产生了更多种类的可溶性因子和更多的白细胞介素-2,并且它们在T细胞疗法能够实现的效应细胞与靶细胞比例下有效地控制了HIV的野生型和突变株。